Arthritis Clinical Trial
Official title:
Rheumatrex High Dose Special Investigation (Regulatory Post Marketing Commitment Plan)
NCT number | NCT01414257 |
Other study ID # | B3211003 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | May 2011 |
Est. completion date | March 2014 |
Verified date | November 2017 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This Investigation is to be performed for the purpose of assessing the following information
in the long-term post-marketing daily medical practice in the patients who receive REUMATOLEX
2 mg Capsule for the treatment of Rheumatoid Arthritis (RA) at the dose higher than 8
mg/week.
1. Condition of occurrence of ADRs
2. Factors considered to affect safety
3. Verification of efficacy
Status | Completed |
Enrollment | 2860 |
Est. completion date | March 2014 |
Est. primary completion date | March 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 17 Years to 99 Years |
Eligibility |
Inclusion Criteria: - Patients need to be administered Rheumatrex in order to be enrolled in the survey - Patients who receive the Rheumatrex at the dose higher than 8 mg/week for the treatment of Rheumatoid Arthritis Exclusion Criteria: - Patients who have been treated with Rheumatrex at the dose higher than 8 mg/week since the days when the high dose therapy for RA was not approved - Patients who have been treated MTX other than Rheumatrex administered Rheumatrex |
Country | Name | City | State |
---|---|---|---|
Japan | University of Occupational and Environmental Health Hospital | Kitakyushu-shi | Fukuoka-ken |
Lead Sponsor | Collaborator |
---|---|
Pfizer |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Treatment-Related Adverse Events | A treatment-related adverse event was any untoward medical occurrence attributed to methotrexate in a participant who received methotrexate. | 24 Weeks | |
Primary | Disease Activity Score (DAS28)-4ESR | Disease activity score based on 28-joint count and erythrocyte sedimentation rate (4 variables) (DAS28-4 [ESR]) was calculated from swollen joint count (SJC) and tender joint count (TJC) using 28 joints count, ESR (mm/hour) and visual analogue scale (VAS) of general health assessed by participant or investigator. Higher score indicated more disease activity. The total scale range of DAS28-4 (ESR) , minimum is 0.0 and maximum can not be specified. DAS28-4 (ESR) >5.1 indicated high disease activity, ?3.2 to ?5.1 indicated moderate disease activity, <3.2 indicated low disease activity, and <2.6 indicated remission. | Baseline and 24 Weeks | |
Primary | Disease Activity Score (DAS28)-4CRP | Disease activity score based on 28-joint count and C-reactive protein (4 variables) (DAS28-4 [CRP]) was calculated from swollen joint count (SJC) and tender joint count (TJC) using 28 joints count, C-reactive protein (CRP, mg/dL) and VAS of general health. The total scale range of DAS28-4 (ESR) , minimum is 0.0 and maximum can not be specified. DAS28-4 (CRP) >4.1 indicated high disease activity, =2.7 to 4.1 indicated moderate disease activity, <2.7 indicated low disease activity, and <2.3 indicated remission. | Baseline and 24 Weeks | |
Primary | Change From Baseline in Disease Activity Score (DAS28)-4ESR | Disease activity score based on 28-joint count and erythrocyte sedimentation rate (4 variables) (DAS28-4 [ESR]) was calculated from swollen joint count (SJC) and tender joint count (TJC) using 28 joints count, ESR (mm/hour) and visual analogue scale (VAS) of general health assessed by participant or investigator. Mean change from baseline in the DAS28-4 (ESR) at Week 24 is calculated. The total scale range can not be specified. | Baseline and 24 Weeks | |
Primary | Change From Baseline in Disease Activity Score (DAS28)-4CRP | Disease activity score based on 28-joint count and C-reactive protein (4 variables) (DAS28-4 [CRP]) was calculated from swollen joint count (SJC) and tender joint count (TJC) using 28 joints count, C-reactive protein (CRP, mg/dL) and VAS of general health. Mean change from baseline in the DAS28-4 (CRP) at Week 24 is calculated. The total scale range can not be specified. | Baseline and 24 Weeks | |
Secondary | Number of Participants With Treatment-Related Serious Adverse Events | A treatment-related adverse event was any untoward medical occurrence attributed to methotrexate in a participant who received methotrexate. A treatment-related serious adverse event was a treatment-related adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; lifethreatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Relatedness to methotrexate was assessed by the investigator. | 24 Weeks | |
Secondary | Number of Participants With Treatment Related Pre-specified Important Serious Adverse Events | Pre-specified important adverse events were 1) Interstitial pneumonia, 2) Pulmonary fibrosis, 3) Hepatic impairment, 4) Renal impairment, 5) Hematopoietic disorder, 6) Infection, and 7) Lymphoma. A treatment-related adverse event was any untoward medical occurrence attributed to methotrexate in a participant who received methotrexate. A treatment-related serious adverse event was a treatment-related adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; lifethreatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Relatedness to methotrexate was assessed by the investigator. | 24 Weeks | |
Secondary | Clinical Efficacy Rate | Clinical efficacy rate, which was defined as the percentage of participants who achieved clinical effectiveness over the total number of assesable effectiveness analysis population, was presented along with the corresponding 2-sided 95% CI. Clinical effectiveness of methotrexate was assessed as "effective" or "ineffective" by the investigator. The assessment was based on the baseline condition of disease control and degree of alleviation from baseline in clinical symptoms and laboratory data. | 24 Weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04228458 -
ThermRheum Version 1
|
N/A | |
Withdrawn |
NCT04976972 -
A Comparison of Patients Receiving a Total Knee Replacement With Robotic Assistance or With Conventional Instrumentation
|
N/A | |
Completed |
NCT04037436 -
Functional Exercise and Nutrition Education Program for Older Adults
|
N/A | |
Completed |
NCT00069342 -
Health Beliefs and Health Behaviors Among Minorities With Rheumatic Diseases
|
||
Completed |
NCT02944448 -
A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee
|
Phase 2 | |
Recruiting |
NCT02498808 -
Interferon-lambda: Novel Biologics for Controlling Neutrophil-mediated Pathology in Rheumatic Diseases?
|
N/A | |
Recruiting |
NCT02777060 -
Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome Measures
|
N/A | |
Enrolling by invitation |
NCT02487888 -
A Study of the Impact of Genetic Testing on Clinical Decision Making and Patient Care
|
N/A | |
Withdrawn |
NCT02136251 -
Total Shoulder Replacement Outcomes With Autologous Bone Graft as Fixator for Glenoid Anchor Peg.
|
||
Completed |
NCT02143206 -
Modifying Exercise for the COPD Patient
|
||
Completed |
NCT01407874 -
A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency
|
Phase 2 | |
Completed |
NCT01285843 -
Periprosthetic Bone Mineral Density After Total Hip Arthroplasty Performed Through a Minimally Invasive Anterior Approach (AMIS) With Either an AMIStem or a Quadra Femoral Component
|
N/A | |
Completed |
NCT00987870 -
Safety and Efficacy of BFH772 in Psoriasis Patients
|
Phase 1/Phase 2 | |
Completed |
NCT01172327 -
Self-Directed Exercise Program for Adults With Arthritis
|
N/A | |
Completed |
NCT00750984 -
A Comparison of Two Different Surgical Techniques for Total Hip Resurfacing
|
N/A | |
Completed |
NCT01184924 -
Evaluation of the Arthritis Foundation Tai Chi Program
|
N/A | |
Active, not recruiting |
NCT00611585 -
A Safety and Efficacy Study of the Birmingham Hip Resurfacing System
|
N/A | |
Completed |
NCT00379184 -
Sensitization in Osteoarthritic Knees
|
N/A | |
Completed |
NCT00175448 -
Comparison of Physiotherapy Versus Home Exercise Following Hip Replacement Surgery
|
N/A | |
Completed |
NCT00403676 -
Nursing Consultation in Out-patient Clinics for Patients With Inflammatory Rheumatic Disease
|
N/A |